ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug

Haematologica

Volumn 94, Issue 11, 2009, Pages 1528-1536

  Chapuy, Bjoern ^a,b   Panse, Melanie ^a   Radunski, Ulf ^a   Koch, Raphael ^a   Wenzel, Dirk ^c   Inagaki, Nobuya ^d   Haase, Detlef ^a   Truemper, Lorenz ^a   Wulf, Gerald G ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

ABC transporter; Chronic myeloid leukemia; Imatinib resistance; Lysosome; Side population

Indexed keywords

ABC TRANSPORTER; BCR ABL PROTEIN; IMATINIB; PROTEIN ABC TRANSPORTER A3; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DETOXIFICATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYSOSOME; MAJOR CLINICAL STUDY; PHENOTYPE; PROTEIN EXPRESSION;

ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DRUG RESISTANCE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYSOSOMES; PIPERAZINES; PYRIMIDINES;

EID: 70449359660     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.008631     Document Type: Article

References (35)

1. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85-109.
2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-293
3. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004. (Pubitemid 36302244)
4. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-1820 (Pubitemid 44394987)
5. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417 (Pubitemid 44903745)
6. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880 (Pubitemid 32743979)
7. O'Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 2006;16:92-99 (Pubitemid 43089618)
8. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004;104:2204-2205 (Pubitemid 39297882)
9. Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lazzarino M. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005;90:979-981 (Pubitemid 41020302)
10. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996;183:1797-1806 (Pubitemid 26134320)
11. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001;98:1166-1173
12. Norwood K, Wang RY, Hirschmann- Jax C, Andreeff M, Brenner MK, Goodell MA, et al. An in vivo propagated human acute myeloid leukemia expressing ABCA3. Leuk Res 2004;28:295-299 (Pubitemid 37550064)
13. Wulf GG, Modlich S, Inagaki N, Reinhardt D, Schroers R, Griesinger F, et al. ABC transporter ABCA3 is expressed in acute myeloid leukemia blast cells and participates in vesicular transport. Haematologica 2004; 89:1395-1397 (Pubitemid 39540580)
14. Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med 2004; 350:1296-1303 (Pubitemid 38375364)
15. Chapuy B, Koch R, Radunski U, Corsham S, Cheong N, Inagaki N, et al. Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia 2008;22: 1576-1586
16. Cheong N, Madesh M, Gonzales LW, Zhao M, Yu K, Ballard PL, et al. Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome. J Biol Chem 2006;281: 9791-9800 (Pubitemid 43864698)
17. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004;104:2940-2942 (Pubitemid 39434984)
18. Ban N, Matsumura Y, Sakai H, Takanezawa Y, Sasaki M, Arai H, et al. ABCA3 as a lipid transporter in pulmonary surfactant biogenesis. J Biol Chem 2007;282:9628-9634
19. Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-1464
20. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia- positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-325
21. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101:4701-4707 (Pubitemid 36857723)
22. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999;94:2056-2064 (Pubitemid 29430422)
23. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, et al. Dynamics of chronic myeloid leukaemia. Nature 2005;435:1267-1270
24. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004;101:14228-14233
25. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7:1028-1034 (Pubitemid 32937383)
26. Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006;108:1370-1373
27. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004;64:2333-2337 (Pubitemid 38523883)
28. Nakanishi T, Shiozawa K, Hassel BA, Ross DD. Complex interaction of BCRP/ABCG2 and imatinib in BCRABL- expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 2006;108:678-684 (Pubitemid 44061370)
29. Efferth T, Gillet JP, Sauerbrey A, Zintl F, Bertholet V, de Longueville F, et al. Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther 2006; 5:1986-1994 (Pubitemid 44336570)
30. Steinbach D, Gillet JP, Sauerbrey A, Gruhn B, Dawczynski K, Bertholet V, et al. ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res 2006;12:4357-4363
31. Stahlman MT, Besnard V, Wert SE, Weaver TE, Dingle S, Xu Y, et al. Expression of ABCA3 in developing lung and other tissues. J Histochem Cytochem 2007;55:71-83. (Pubitemid 46032617)
32. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinibtreated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006; 12:1181-1184 (Pubitemid 44527354)
33. Mulugeta S, Gray JM, Notarfrancesco KL, Gonzales LW, Koval M, Feinstein SI, et al. Identification of LBM180, a lamellar body limiting membrane protein of alveolar type II cells, as the ABC transporter protein ABCA3. J Biol Chem 2002;277:22147-22155 (Pubitemid 34967179)
34. Nagata K, Yamamoto A, Ban N, Tanaka AR, Matsuo M, Kioka N, et al. Human ABCA3, a product of a responsible gene for abca3 for fatal surfactant deficiency in newborns, exhibits unique ATP hydrolysis activity and generates intracellular multilamellar vesicles. Biochem Biophys Res Commun 2004;324:262-268 (Pubitemid 39311488)
35. Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 2005;33:1503-1512 (Pubitemid 41323999)